Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Chugai Offers 5% Pay Raise in 30-Year-Old Model Case
April 4, 2024
- Mochida, Meiji Adds China for Epadel Sales Collaboration
April 4, 2024
- Eisai to Divest Rights to 2 CNS Drugs to UK’s CNX in France, Algeria
April 4, 2024
- Sawai Closes Sale of US Business to Taiwan CDMO
April 4, 2024
- Sumitomo Offloads Entire Stake in Roivant as Earnings Tank
April 3, 2024
- Daiichi’s TROP2 ADC Accepted for US FDA Review in Breast Cancer
April 3, 2024
- Axcelead-Teijin Drug Discovery Joint Venture Now Up and Running
April 2, 2024
- MS Med Copaxone Transferred to Teva Takeda Pharma
April 2, 2024
- Takeda to Hand Over Nihon Pharma to Alinamin in July
April 2, 2024
- Cheplapharm to Take Over 5 Brands from Clinigen in Japan
April 2, 2024
- Aculys Pharma Poaches Takeda Veteran as New CEO
April 2, 2024
- New Ono Chief Eager to Go Solo in US, Europe; BTK Med 1st Shield against Opdivo Patent Cliff
April 1, 2024
- Ying Chen Named as President of Bayer Holding in Japan
April 1, 2024
- Asahi Kasei Grabs Japan Commercial Rights to Doptelet’s ITP Use
April 1, 2024
- 5 Otsuka Execs Reel in 100 Million-Plus Pay in 2023: Securities Filing
April 1, 2024
- Chugai Workforce Down 200 in 2023 after Voluntary Buyout: Securities Report
April 1, 2024
- “Puberulic Acid” in Beni-Koji Supplements; Kobayashi Wants to Keep Healthcare Biz
April 1, 2024
- Uber Eats Launches Delivery Service for Prescription Drugs in Japan
March 29, 2024
- Taiho Bags Label Update for Lonsurf Combo Use with Bevacizumab
March 29, 2024
- BIKEN Files Nasal Flu Vaccine in Japan
March 29, 2024
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…